Amiel Gross serves as Head of Legal at the Center for Breakthrough Medicines at Philadelphia since 2020. He focuses on building and managing the legal function of a rapidly growing biotechnology company in cell and gene therapy manufacturing.
Gross is responsible for ensuring the business strategies and policies are aligned in full recognition of all legal implications, obligations, and risks.
Counseling executives and senior management, negotiating complex commercial transactions, facilitating strategic alliances and supporting a range of legal issues arising in the course of highly-regulated biotechnology business operations are the focus of Gross’ multi-disciplinary life science practice.
This professional oversight responsibility and hands-on experience across array of subject matters. These subjects include licensing deals, master services agreements, procurement contracts, intellectual property, corporate affairs, sponsored R&D collaborations, FDA regulatory and compliance, litigation, labor and employment, cybersecurity and privacy.
Amiel Gross holds a Bachelor of Arts Degree from the Southwestern University and a Doctor of Law Degree from The University of Texas School of Law.
General corporate counsel, life science industry, biotechnology, industry knowledge, pharmaceutical law, biopharmaceuticals, corporate law, licensing, regulatory compliance. He is also highly experienced at business transactions, commercial contracts, CDMO, CGT, cell and gene therapy are Amiel Gross’ skills.
